Dr Kirsten Coupland
Postdoctoral Researcher
School of Biomedical Sciences and Pharmacy (Human Physiology)
- Email:kirsten.coupland@newcastle.edu.au
- Phone:(02) 40421611
Career Summary
Biography
My Research
I study complex brain health issues to find new treatments that can improve outcomes for patients. Specifically, I focus on the composition and behaviour of cerebrospinal and interstitial fluid (fluid in the brain and surrounding areas) in diseases like stroke, where a clot blocks blood supply and results in brain damage. Even though this fluid is crucial in many neurological diseases, we don't know much about it. In fact, I'm the only researcher in Australia studying how it contributes to stroke outcomes.
Some of the projects I am currently working on include:
The role of pressure inside of the skull on stroke severity
We have found that increased pressure inside the skull after stroke can change the way blood is delivered to the stroke site. It seems that this increase in pressure might be due to reduced outflow of cerebrospinal fluid from the skull. By studying this connection, we hope to gain insights into how changes in pressure affect the movement of cerebrospinal fluid and potentially contribute to how bad a stroke ends up being.
Mimicking hypothermia to improve stroke recovery
We are exploring how hypothermia (lowering the body temperature) protects the brain after stroke. There is a lot of evidence that hypothermia improves patient’s recovery from stroke but because of how tricky it is to do this, we cannot use it in the hospital setting. So, we want to understand how hypothermia improves stroke recovery so that we can design new drugs that have the same effect.
Understanding what happens in the brain following stroke
In collaboration with researchers at the University of Adelaide, we are studying how the proteins, fats and chemicals of cerebrospinal fluid and brain tissue change after a stroke. By analysing the changes in protein composition at different time points after stroke we can better understand what is going on in the brain and cerebrospinal fluid and how this influences how much damage a stroke causes.
The impact of statins on stroke outcome
An important aspect of our research involves investigating the protective effects of statins (cholesterol-lowering drugs), in the context of stroke. There is a lot of published evidence that statins improve stroke outcome, but again this has not been easy to move into the hospital setting. We want to understand exactly how statins reduce how bad a stroke is so we can then improve patient outcomes.
Reducing stroke severity through understanding disrupted brain signals
After someone has had a stroke the electrical signals in their brain become disrupted. This disrupted signalling can affect all kinds of things in the brain and can make a stroke far worse. By better understanding these signals, we can figure out the best way to stop them doing further damage to the brain.
Partnerships
I work closely with both industry partners and healthcare professionals to make sure my studies are relevant and can be applied in real-world situations. I've also established collaborations with local and international institutions to gain a better understanding of this important system. My collaborators include the University of Newcastle, NSW Health, University of Adelaide, Universität Bern, and Karolinska Institutët.
Research Profile
My work tackles challenging neurological health issues to develop novel therapeutics that improve patient outcomes. I do this by focusing on the composition and dynamics of cerebrospinal/interstitial fluid (CSF/ISF) in neurological disease, particularly in ischaemic stroke. CSF/ISF is a poorly characterised system despite its importance in numerous neurological diseases, and I am the only researcher in Australia investigating its role in stroke pathology.
I currently hold several grants as CIA, totalling ~$1 million from the NHMRC and industry to investigate different aspects of this poorly understood system and its contributions to disease. For these projects I combine my extensive microsurgical skills and powerful in vivo stroke model with molecular biology (such as mass spectrometry) and confocal microscopy. My close ties with industry and the clinic inform the design of my studies to ensure my work is ready to be translated into real world impact. I have built a powerful network of local (University of Newcastle, NSW Health), national (University of Adelaide) and international (Universität Bern, Karolinska Institutët) collaborations to better understand this important system.
My research combines skills in microsurgery with techniques like mass spectrometry (a way to analyse molecules) and confocal microscopy (a powerful type of microscope) to examine the fluid and its effects on the brain during stroke.
Current research themes
- The relationship between elevated intracranial pressure and reduced cerebrospinal fluid efflux from the cranial space after stroke.
- Identifying the molecular underpinnings of hypothermia as a powerful therapeutic to improve stroke outcome.
- Temporal profile of cerebrospinal fluid and brain tissue proteome after stroke.
- Understanding the protective effect of statins (cholesterol-lowering drugs) after stroke.
- Peri-infarct depolarisations and their relationship to altered post-stroke physiology.
Our lab is currently recruiting 3rd year, Honours, Masters and PhD students. Please reach out to discuss your research interests.
We also have many collaborations with both industry and other research groups arnd are always happy to discuss our work further with potential partners/collaborators.
Qualifications
- Doctor of Philosophy, University of New South Wales
- Bachelor of Science (Honours), University of New South Wales
- Diploma in Innovation Management, University of New South Wales
Keywords
- Cerebrospinal fluid
- Cerebrovasculature
- Neuroscience
- Stroke
Languages
- English (Mother)
Fields of Research
Code | Description | Percentage |
---|---|---|
320899 | Medical physiology not elsewhere classified | 30 |
320199 | Cardiovascular medicine and haematology not elsewhere classified | 30 |
320903 | Central nervous system | 40 |
Professional Experience
UON Appointment
Title | Organisation / Department |
---|---|
Postdoctoral Researcher | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Academic appointment
Dates | Title | Organisation / Department |
---|---|---|
16/2/2015 - 27/4/2018 | Postdoctoral Researcher | Karolinska Institute Neurobiology, Care Science and Society Sweden |
1/3/2010 - 23/12/2011 | Research Assistant | NeuRA Ageing and Neurodegeneration Australia |
Awards
Award
Year | Award |
---|---|
2021 |
Cardiovascular Research Network Mid-career researcher award Cardiovascular Research Network |
Nomination
Year | Award |
---|---|
2013 |
AMPlify Brightsparks AMP Limited |
Prize
Year | Award |
---|---|
2012 |
Junior Oral Presentation Prize Prince of Wales Childrens Hospital |
2012 |
Student Oral Presentation Australasian GeneMappers Conference |
2010 |
Best performance in INOV4101-4301: Innovation in practise Meat and Livestock Australia (MLA) |
Scholarship
Year | Award |
---|---|
2014 |
Student Oral Presentation The Royal Society |
Invitations
Participant
Year | Title / Rationale |
---|---|
2015 | Synthetic Biology Summer School |
Speaker
Year | Title / Rationale |
---|---|
2014 | Commonwealth Science Conference |
2013 | Amplify Festival Brightsparks |
Teaching
Code | Course | Role | Duration |
---|---|---|---|
PHAR6704 |
Pharmacology of chronic conditions School of Biomedical Sciences and Pharmacy |
Lecturer | 1/3/2021 - 25/6/2021 |
HUBS2407 |
Experimental design and laboratory skills in medical research School of Biomedical Sciences and Pharmcy, The University of Newcastle |
Lecturer | 2/3/2020 - 26/6/2020 |
0000 |
Erasmus Internship Karolinska Institute |
In-lab supervisor | 13/4/2015 - 14/9/2015 |
0000 |
Erasmus internship Karolinska Institute |
In-lab supervisor | 4/9/2017 - 4/12/2017 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (1 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2022 |
Ong L, Ilicic M, Hood R, Warren K, Coupland K, 'Targeting Adult Neurogenesis for Brain Recovery After Stroke: The Next Frontier in Stroke Medicine', Regenerative Therapies in Ischemic Stroke Recovery, Springer, Singapore (2022)
|
Journal article (22 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2024 |
Kuppuswamy A, Billinger S, Coupland KG, English C, Kutlubaev MA, Moseley L, et al., 'Mechanisms of Post-Stroke Fatigue: A Follow-Up From the Third Stroke Recovery and Rehabilitation Roundtable.', Neurorehabil Neural Repair, 38 52-61 (2024) [C1]
|
Nova | |||||||||
2024 |
Dzator JSA, Smith RA, Coupland KG, Howe PRC, Griffiths LR, 'Associations between Cerebrovascular Function and the Expression of Genes Related to Endothelial Function in Hormonal Migraine.', Int J Mol Sci, 25 (2024) [C1]
|
Nova | |||||||||
2024 |
English C, Simpson DB, Billinger SA, Churilov L, Coupland KG, Drummond A, et al., 'A roadmap for research in post-stroke fatigue: Consensus-based core recommendations from the third Stroke Recovery and Rehabilitation Roundtable.', Neurorehabil Neural Repair, 38 7-18 (2024) [C1]
|
Nova | |||||||||
2024 |
English C, Simpson DB, Billinger SA, Churilov L, Coupland KG, Drummond A, et al., 'A roadmap for research in post-stroke fatigue: Consensus-based core recommendations from the third Stroke Recovery and Rehabilitation Roundtable.', Int J Stroke, 19 133-144 (2024) [C1]
|
Nova | |||||||||
2023 |
Hinwood M, Ilicic M, Gyawali P, Coupland K, Kluge MG, Smith A, et al., 'Psychological Stress Management and Stress Reduction Strategies for Stroke Survivors: A Scoping Review', Annals of behavioral medicine : a publication of the Society of Behavioral Medicine, 57 111-130 (2023) [C1] BACKGROUND: Stroke can be a life-changing event, with survivors frequently experiencing some level of disability, reduced independence, and an abrupt lifestyle change. Not surpris... [more] BACKGROUND: Stroke can be a life-changing event, with survivors frequently experiencing some level of disability, reduced independence, and an abrupt lifestyle change. Not surprisingly, many stroke survivors report elevated levels of stress during the recovery process, which has been associated with worse outcomes. PURPOSE: Given the multiple roles of stress in the etiology of stroke recovery outcomes, we aimed to scope the existing literature on stress management interventions that have been trialed in stroke survivors. METHODS: We performed a database search for intervention studies conducted in stroke survivors which reported the effects on stress, resilience, or coping outcome. Medline (OVID), Embase (OVID), CINAHL (EBSCO), Cochrane Library, and PsycInfo (OVID) were searched from database inception until March 11, 2019, and updated on September 1, 2020. RESULTS: Twenty-four studies met the inclusion criteria. There was significant variation in the range of trialed interventions, as well as the outcome measures used to assess stress. Overall, just over half (13/24) of the included studies reported a benefit in terms of stress reduction. Acceptability and feasibility were considered in 71% (17/24) and costs were considered in 17% (4/24) of studies. The management of stress was rarely linked to the prevention of symptoms of stress-related disorders. The overall evidence base of included studies is weak. However, an increase in the number of studies over time suggests a growing interest in this subject. CONCLUSIONS: Further research is required to identify optimum stress management interventions in stroke survivors, including whether the management of stress can ameliorate the negative impacts of stress on health.
|
Nova | |||||||||
2023 |
Warren KE, Coupland KG, Hood RJ, Kang L, Walker FR, Spratt NJ, 'Movement of cerebrospinal fluid tracer into brain parenchyma and outflow to nasal mucosa is reduced at 24 h but not 2 weeks post-stroke in mice', Fluids and Barriers of the CNS, 20 (2023) [C1] Background: Recent data indicates that cerebrospinal fluid (CSF) dynamics are disturbed after stroke. Our lab has previously shown that intracranial pressure rises dramatically 24... [more] Background: Recent data indicates that cerebrospinal fluid (CSF) dynamics are disturbed after stroke. Our lab has previously shown that intracranial pressure rises dramatically 24¿h after experimental stroke and that this reduces blood flow to ischaemic tissue. CSF outflow resistance is increased at this time point. We hypothesised that reduced transit of CSF through brain parenchyma and reduced outflow of CSF via the cribriform plate at 24¿h after stroke may contribute to the previously identified post-stroke intracranial pressure elevation. Methods: Using a photothrombotic permanent occlusion model of stroke in C57BL/6 adult male mice, we examined the movement of an intracisternally infused 0.5% Texas Red dextran throughout the brain and measured tracer efflux into the nasal mucosa via the cribriform plate at 24¿h or two weeks after stroke. Brain tissue and nasal mucosa were collected ex vivo and imaged using fluorescent microscopy to determine the change in CSF tracer intensity in these tissues. Results: At 24¿h after stroke, we found that CSF tracer load was significantly reduced in brain tissue from stroke animals in both the ipsilateral and contralateral hemispheres when compared to sham. CSF tracer load was also reduced in the lateral region of the ipsilateral hemisphere when compared to the contralateral hemisphere in stroke brains. In addition, we identified an 81% reduction in CSF tracer load in the nasal mucosa in stroke animals compared to sham. These alterations to the movement of CSF-borne tracer were not present at two weeks after stroke. Conclusions: Our data indicates that influx of CSF into the brain tissue and efflux via the cribriform plate are reduced 24¿h after stroke. This may contribute to reported increases in intracranial pressure at 24¿h after stroke and thus worsen stroke outcomes.
|
Nova | |||||||||
2023 |
Oliveira DV, Coupland KG, Shao W, Jin S, Del Gaudio F, Wang S, et al., 'Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model.', EMBO Mol Med, 15 e16556 (2023) [C1]
|
||||||||||
2023 |
Dzator JSA, Coupland KG, Howe PRC, 'Exploring the effects of resveratrol supplementation on cerebrovascular function in hormonal migraineurs: A pilot study', IBRO Neuroscience Reports, 15 310-319 (2023) [C1] Background: Past research suggests that hormonal migraineurs may have poorer cerebrovascular function than women who do not suffer from migraine. Resveratrol, a vasoactive phytoes... [more] Background: Past research suggests that hormonal migraineurs may have poorer cerebrovascular function than women who do not suffer from migraine. Resveratrol, a vasoactive phytoestrogen, has been shown to improve cerebrovascular function in several populations but has never been tested in hormonal migraineurs. Aim: To investigate the effects of 3-month resveratrol supplementation on the cerebrovascular function of hormonal migraineurs. Methods: We conducted a randomised, double-blind, placebo-controlled, crossover intervention pilot study with resveratrol (150 mg/d for 3 months) in ten hormonal migraineurs (mean age: 37.2 ± 2.6 years). Participants visited the University of Newcastle's Clinical Nutrition Research Centre where quality of life and disability, and cerebrovascular function were assessed. Quality of life and disability were examined using Migraine-Specific Quality of Life, Headache Impact Test-6 and the Migraine Disability Assessment. Cerebrovascular function was determined using transcranial Doppler ultrasound to bilaterally measure blood flow velocity in the middle and posterior cerebral arteries at rest and in response to a hypercapnic stimulus. Cerebrovascular responsiveness to a cognitive task battery was also measured bilaterally in the middle cerebral arteries. Results: Compared to placebo, blood flow velocity in the right posterior cerebral artery was significantly higher (P = 0.041) following resveratrol supplementation. No other significant differences in cerebrovascular function between resveratrol and placebo treatments were observed. Baseline correlation analyses revealed higher blood flow velocities in the middle and posterior cerebral arteries were associated with better quality of life and less disability. However, higher cerebrovascular responsiveness to hypercapnia in the posterior circulation was associated with higher migraine-related disability and poorer migraine-related quality of life. Conclusion: In this pilot we found evidence that resveratrol may increase blood flow velocity in the right posterior cerebral artery in hormonal migraineurs. Larger cohorts are required confirm this effect and its potential relationship to migraine in premenopausal women.
|
Nova | |||||||||
2022 |
Dzator JSA, Howe PRC, Coupland KG, Wong RHX, 'A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine', Nutrients, 14 (2022) [C1] Resveratrol, a vasoactive phytoestrogen, has beneficial effects on cerebrovascular func-tion. Previous research has shown that hormonal migraineurs have poorer cerebrovascular fun... [more] Resveratrol, a vasoactive phytoestrogen, has beneficial effects on cerebrovascular func-tion. Previous research has shown that hormonal migraineurs have poorer cerebrovascular function than non-migraineur women. We aimed to investigate if resveratrol supplementation for three months could reduce the hormonal migraine burden index (HMBI: the number of days with menstrual migraine per month), reduce migraine-related disability and improve migraine-related quality of life. A randomised, double-blind, placebo-controlled, crossover, intervention trial was con-ducted in 62 hormonal migraineurs (mean age: 37.5 ± 0.8 years). Participants consumed 75 mg of resveratrol or matching placebo capsules twice daily for three months before crossing over to the other treatment arm. Participants completed a daily diary and the Headache Impact Test-6¿, Migraine Disability Assessment and Migraine-Specific Quality of Life questionnaires at months 0, 3 and 6. The HMBI was the primary outcome and was calculated using data extracted from the par-ticipant¿s diary. No differences in the HMBI (p = 0.895), the Headache Impact Test-6¿, the Migraine Disability Assessment and Migraine-Specific Quality of Life were found between the resveratrol and placebo treatments. Resveratrol supplementation for three months did not affect the HMBI, the migraine-related disability or quality of life measures in our cohort of hormonal migraineurs.
|
Nova | |||||||||
2021 |
Omileke D, Pepperall D, Bothwell SW, Mackovski N, Azarpeykan S, Beard DJ, et al., 'Ultra-Short Duration Hypothermia Prevents Intracranial Pressure Elevation Following Ischaemic Stroke in Rats', FRONTIERS IN NEUROLOGY, 12 (2021) [C1]
|
Nova | |||||||||
2021 |
Omileke D, Azarpeykan S, Bothwell SW, Pepperall D, Beard DJ, Coupland K, et al., 'Short-duration hypothermia completed prior to reperfusion prevents intracranial pressure elevation following ischaemic stroke in rats', SCIENTIFIC REPORTS, 11 (2021) [C1]
|
Nova | |||||||||
2021 |
Omileke D, Bothwell SW, Pepperall D, Beard DJ, Coupland K, Patabendige A, Spratt NJ, 'Decreased Intracranial Pressure Elevation and Cerebrospinal Fluid Outflow Resistance: A Potential Mechanism of Hypothermia Cerebroprotection Following Experimental Stroke', Brain Sciences, 11 (2021) [C1]
|
Nova | |||||||||
2021 |
Dzator JSA, Howe PRC, Griffiths LR, Coupland KG, Wong RHX, 'Cerebrovascular Function in Hormonal Migraine: An Exploratory Study', FRONTIERS IN NEUROLOGY, 12 (2021) [C1]
|
Nova | |||||||||
2021 |
Omileke D, Bothwell S, Beard D, MacKovski N, Azarpeykan S, Coupland K, et al., 'Short-duration hypothermia induction in rats using
models for studies examining clinical relevance and
mechanisms', Journal of Visualized Experiments, 169 (2021) [C1]
|
Nova | |||||||||
2018 |
Coupland K, Lendahl U, Karlström H, 'Role of NOTCH3 mutations in the cerebral small vessel disease cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy', Stroke, 49 2793-2800 (2018) [C1]
|
||||||||||
2016 |
Coupland KG, Kim WS, Halliday GM, Hallupp M, Dobson-Stone C, Kwok JBJ, 'Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease', PLOS ONE, 11 (2016) [C1]
|
||||||||||
2015 |
Coupland KG, Kim WS, Halliday GM, Hallupp M, Dobson-Stone C, Kwok JBJ, 'Effect of PSEN1 Mutations on MAPT Methylation in Early-Onset Alzheimer's Disease', CURRENT ALZHEIMER RESEARCH, 12 745-751 (2015)
|
||||||||||
2014 |
Coupland KG, Mellick GD, Silburn PA, Mather K, Armstrong NJ, Sachdev PS, et al., 'DNA Methylation of the MAPT Gene in Parkinson's Disease Cohorts and Modulation by Vitamin E In Vitro', MOVEMENT DISORDERS, 29 1606-1614 (2014)
|
||||||||||
Show 19 more journal articles |
Conference (2 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2021 |
Coupland KG, Skerrett-Byrne DA, Sorby-Adams AJ, Turner RJ, Spratt NJ, 'Mapping temporal changes in cerebrospinal fluid composition after stroke to identify novel therapeutic targets for future drug discovery', INTERNATIONAL JOURNAL OF STROKE (2021)
|
||||
2015 | Kwok J, Coupland K, Mellick G, Mather K, Thalamuthu A, Armstrong N, et al., 'Genome-wide association study identifies the SLC2A14 gene on chromosome 12P13 as a trans-acting locus for methylation of MAPT gene', JOURNAL OF NEUROCHEMISTRY, Cairns, AUSTRALIA (2015) |
Preprint (2 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2022 |
Oliveira DV, Coupland KG, Jin S, Del Gaudio F, Wang S, Fox R, et al., 'NOTCH3 active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model (2022)
|
|||||||
2021 |
Omileke D, Azarpeykan S, Bothwell S, Pepperall D, Beard D, Coupland K, et al., 'Hypothermia and rewarming prior to reperfusion, prevents intracranial pressure elevation after ischaemic stroke in rats: an investigation to define the importance of cooling during reperfusion (2021)
|
Grants and Funding
Summary
Number of grants | 22 |
---|---|
Total funding | $1,867,618 |
Click on a grant title below to expand the full details for that specific grant.
20231 grants / $19,000
Determining how hypothermia protects the brain after a stroke$19,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Kirsten Coupland, Professor Neil Spratt |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2300946 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20222 grants / $982,156
New pathways to improved stroke outcome: the importance of managing intracranial pressure$503,385
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Kirsten Coupland, Professor Neil Spratt |
Scheme | Ideas Grants |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2024 |
GNo | G2100571 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
Mapping temporal changes in cerebrospinal fluid composition after stroke to identify novel therapeutic targets for future drug discovery$478,771
Funding body: CSL Innovation Pty Ltd
Funding body | CSL Innovation Pty Ltd |
---|---|
Project Team | Doctor Kirsten Coupland, Professor Neil Spratt, Doctor David Skerrett-Byrne, Renee Turner |
Scheme | Research Acceleration Initiative |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2023 |
GNo | G2100633 |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | Y |
20214 grants / $15,300
The capacity of statins to improve stroke outcome: influence of perfusion lesion volume and collateral supply$10,000
Funding body: Priority Research Centre for Stroke and Brain Injury
Funding body | Priority Research Centre for Stroke and Brain Injury |
---|---|
Project Team | Coupland K. G., Spratt N., Lillicrap T. |
Scheme | Strategic Investment Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | Other Public Sector - Local |
Category | 2OPL |
UON | N |
IBRO Meeting support$2,300
Funding body: International Brain Research Organization
Funding body | International Brain Research Organization |
---|---|
Project Team | Coupland K.G., Rank M., Ong L. K., Hood R., Beard D. |
Scheme | IBRO meeting support |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | C3212 - International Not for profit |
Category | 3212 |
UON | N |
Cardiovascular Research Network Professional Development Award$2,000
Funding body: Cardiovascular Research Network
Funding body | Cardiovascular Research Network |
---|---|
Project Team | Coupland K. G. |
Scheme | Professional Development Award |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | N |
Capacity of statins to improve stroke outcome: clearing a path to implementation$1,000
Funding body: National Heart Foundation of Australia
Funding body | National Heart Foundation of Australia |
---|---|
Project Team | Doctor Kirsten Coupland |
Scheme | NSW Cardiovascular Research Network (CVRN) Professional Development Award |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2101202 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
20201 grants / $12,162
Mapping changes in cerebrospinal fluid composition after stroke to identify novel therapeutic targets for future drug discovery.$12,162
Funding body: John Hunter Hospital Charitable Trust
Funding body | John Hunter Hospital Charitable Trust |
---|---|
Project Team | Doctor Kirsten Coupland, Professor Neil Spratt, Doctor David Skerrett-Byrne |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | G2000282 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
20191 grants / $800
Travel grant$800
Funding body: NEWCASTLE UNIVERSITY
Funding body | NEWCASTLE UNIVERSITY |
---|---|
Project Team | Coupland K. G. |
Scheme | Faculty of Health and Medicine Travel Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | N |
20182 grants / $33,400
New tools to tackle familial vascular dementia$19,400
Funding body: Karolinska Institutet
Funding body | Karolinska Institutet |
---|---|
Scheme | Karolinska Institutet Forskningsbidrag |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2019 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
New tools to tackle familial vascular dementia$14,000
Funding body: Karolinska Institutet
Funding body | Karolinska Institutet |
---|---|
Scheme | Karolinska Institutet Fonden Geriatrik |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2020 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
20174 grants / $761,500
HMRI Early Career Research Fellowship in Stroke$712,500
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Neil Spratt, Doctor Kirsten Coupland |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2022 |
GNo | G1701347 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Understanding the role of Notch3 in familial vascular dementia and its potential use in immunotherapies$21,000
Funding body: Karolinska Institutet Fonden Geriatrik
Funding body | Karolinska Institutet Fonden Geriatrik |
---|---|
Scheme | Karolinska Institutet Fonden Geriatrik |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Research Grant$17,000
Funding body: Loo och Hans Ostermans
Funding body | Loo och Hans Ostermans |
---|---|
Scheme | Loo och Hans Ostermans |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Foundation Grant$11,000
Funding body: Gamla Tjänarinnor
Funding body | Gamla Tjänarinnor |
---|---|
Scheme | Gamla Tjänarinnor |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
20164 grants / $20,000
Institutional grant$8,300
Funding body: Karolinska Institutet Fonden Geriatrik
Funding body | Karolinska Institutet Fonden Geriatrik |
---|---|
Scheme | Karolinska Institutet Fonden Geriatrik |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Foundation Grant$5,000
Funding body: Gamla Tjänarinnor
Funding body | Gamla Tjänarinnor |
---|---|
Scheme | Gamla Tjänarinnor |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Research Grant$4,200
Funding body: Strokeförbundet
Funding body | Strokeförbundet |
---|---|
Scheme | Strokeförbundet |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Research Grant$2,500
Funding body: Stohnes Stiftelse
Funding body | Stohnes Stiftelse |
---|---|
Scheme | Stohnes Stiftelse |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
20153 grants / $23,300
Institutional grant$15,000
Funding body: Karolinska Institutet Fonden Geriatrik
Funding body | Karolinska Institutet Fonden Geriatrik |
---|---|
Scheme | Karolinska Institutet Fonden Geriatrik |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2016 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Foundation Grant$6,700
Funding body: Gamla Tjänarinnor
Funding body | Gamla Tjänarinnor |
---|---|
Scheme | Gamla Tjänarinnor |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2016 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Research Grant$1,600
Funding body: Stohnes Stiftelse
Funding body | Stohnes Stiftelse |
---|---|
Scheme | Stohnes Stiftelse |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2016 |
GNo | |
Type Of Funding | International - Non Competitive |
Category | 3IFB |
UON | N |
Research Collaborations
The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.
Country | Count of Publications | |
---|---|---|
Australia | 22 | |
United Kingdom | 8 | |
Sweden | 6 | |
United States | 5 | |
Canada | 3 | |
More... |
News
News • 8 Nov 2021
$4.5m in NHMRC Ideas Grants supports quest to improve human health
University of Newcastle researchers will explore new stroke prevention therapies, preterm birth interventions and a dual approach to breast cancer treatment with the support of $4.5m in National Health and Medical Research Council (NHMRC) Ideas grants.
Dr Kirsten Coupland
Position
Postdoctoral Researcher
Spratt Lab
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing
Focus area
Human Physiology
Contact Details
kirsten.coupland@newcastle.edu.au | |
Phone | (02) 40421611 |
Office
Room | MS-503 |
---|---|
Building | Medical Sciences Building |
Location | Callaghan University Drive Callaghan, NSW 2308 Australia |